Literature DB >> 24882614

Drug survival in biologic therapy. Do we know what it means? Can we calculate it?

J M Carrascosa1, J Notario2.   

Abstract

Mesh：

Year:  2014        PMID： 24882614     DOI： 10.1016/j.ad.2014.04.004

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN： 0001-7310


× No keyword cloud information.
  4 in total

1.  Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients.

Authors:  Coco Dekkers; Mehran Alizadeh Aghdam; Marlies de Graaf; André C Knulst; Yolanda Meijer; Juul M P A van den Reek; Marike B Stadermann; Heike Röckmann
Journal:  Pediatr Allergy Immunol       Date:  2021-01-18       Impact factor: 6.377

2.  Therapeutic response and survival time of immunobiologicals in patients with moderate to severe psoriasis.

Authors:  Cynthia Cristina Ferreira Mota; Ricardo Romiti; Marcelo Arnone; Andre Luís da Silva Hirayama; Maria Denise Fonseca Takahashi
Journal:  An Bras Dermatol       Date:  2021-11-20       Impact factor: 1.896

3.  Ustekinumab Drug Survival in Patients with Psoriasis: A retrospective Study of Real Clinical Practice.

Authors:  Cristina Galache Osuna; Borja Gómez-Vila; Javier Aubán Pariente; Beatriz Vázquez Losada; Celia Gómez de Castro; Sheila Requena López; Álvaro de Dios Velázquez; Laura Palacios García; Lucía Ordoñez Fernández; Santiago Gómez Diez; Francisco Vázquez López; Jorge Santos-Juanes
Journal:  Medicina (Kaunas)       Date:  2020-10-30       Impact factor: 2.430

4.  Use of Biological Treatments in Elderly Patients with Skin Psoriasis in the Real World.

Authors:  Cristina Galache Osuna; Sebastián Reyes García; Jimena Carrero Martín; Virginia García Jiménez; Francisco Vázquez López; Jorge Santos-Juanes
Journal:  Life (Basel)       Date:  2021-12-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.